• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
NICE Recommends Isatuximab + POM/Dex for people with difficult-to-treat multiple myeloma

NICE Recommends Isatuximab + POM/Dex for people with difficult-to-treat multiple myeloma

by MM360 Staff | Nov 24, 2020 | Featured News, Myeloma News

NICE has recommended Isatuximab for people with difficult-to-treat multiple myeloma (MM). Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed...
Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News

A new study published in Cancer Medicine demonstrates that Hypercalcemia is associated with poor rates of survival in patients with newly diagnosed myeloma (NDMM). The researchers retrospectively evaluated the prognostic impact and mechanism of hypercalcemia in 357...
Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult

Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult

by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News

Smoldering multiple myeloma (SMM) is a plasma cell disorder with the potential to evolve to multiple myeloma. Several risk stratification models have been used to identify patients at high risk who may be eleigible for early treaetment. In an article published today...
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1

by MM360 Staff | Nov 18, 2020 | Featured News, Myeloma News

Cellectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM). Cellectis worked...
Once-weekly Regimen of Selinexor, Bortezomib, and Dexamethasone Slows Progression of RRMM

Once-weekly Regimen of Selinexor, Bortezomib, and Dexamethasone Slows Progression of RRMM

by MM360 Staff | Nov 14, 2020 | Featured News, Myeloma News

A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. The results from the BOSTON study demonstrate that the once-weekly...
« Older Entries
Next Entries »

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT